WO2026018222 - ADMINISTERING CHOLECALCIFEROL TRANSDERMALLY
National phase entry is expected:
Publication Number
WO/2026/018222
Publication Date
22.01.2026
International Application No.
PCT/IB2025/057319
International Filing Date
18.07.2025
Title **
[English]
ADMINISTERING CHOLECALCIFEROL TRANSDERMALLY
[French]
ADMINISTRATION PAR VOIE TRANSDERMIQUE DE CHOLÉCALCIFÉROL
Applicants **
EPTIVA THERAPEUTICS LTD.
Inventors
FIELD, Mark J.
Priority Data
63/672,823
18.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2110 | |
| EPO | Filing, Examination, Granting | 9698 | |
| Japan | Filing, Examination, Granting | 2264 | |
| South Korea | Filing, Examination, Granting | 2236 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,048
Contact Us
Abstract[English]
Disclosed are methods for increasing a patient's levels of vitamin D through transdermal administration of cholecalciferol. The patient may be identified as being at risk of calcidiol accumulation, such as having chronic kidney disease or being at risk of developing chronic kidney disease. The patient is administered a transdermal formulation of cholecalciferol. The transdermal formulation beneficially increases serum calcitriol in the patient without disproportionally accumulating serum calcidiol.[French]
L'invention concerne des procédés d'augmentation des taux de vitamine D d'un patient par administration transdermique de cholécalciférol. Le patient peut être identifié comme présentant un risque d'accumulation de calcidiol, tel que présentant une maladie rénale chronique ou présentant un risque de développer une maladie rénale chronique. Le patient se voit administrer une formulation transdermique de cholécalciférol. La formulation transdermique augmente avantageusement le calcitriol sérique chez le patient sans accumulation disproportionnelle de calcidiol sérique.